HRP20201959T1 - Liječenje neuroloških bolesti - Google Patents
Liječenje neuroloških bolesti Download PDFInfo
- Publication number
- HRP20201959T1 HRP20201959T1 HRP20201959TT HRP20201959T HRP20201959T1 HR P20201959 T1 HRP20201959 T1 HR P20201959T1 HR P20201959T T HRP20201959T T HR P20201959TT HR P20201959 T HRP20201959 T HR P20201959T HR P20201959 T1 HRP20201959 T1 HR P20201959T1
- Authority
- HR
- Croatia
- Prior art keywords
- lys
- peptide according
- peptide
- amino acid
- seq
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims 7
- 208000012902 Nervous system disease Diseases 0.000 title claims 6
- 208000025966 Neurological disease Diseases 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 19
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical group CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 claims 9
- 125000006850 spacer group Chemical group 0.000 claims 7
- 238000011321 prophylaxis Methods 0.000 claims 6
- -1 7-aminoheptanoyl Chemical group 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 208000024827 Alzheimer disease Diseases 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 3
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 229930195729 fatty acid Natural products 0.000 claims 2
- 239000000194 fatty acid Substances 0.000 claims 2
- 150000004665 fatty acids Chemical class 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 229920003169 water-soluble polymer Polymers 0.000 claims 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 1
- 206010059245 Angiopathy Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 108010016626 Dipeptides Proteins 0.000 claims 1
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 claims 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 1
- 208000004547 Hallucinations Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000037048 Prodromal Symptoms Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 230000019771 cognition Effects 0.000 claims 1
- 230000003920 cognitive function Effects 0.000 claims 1
- 125000003074 decanoyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 claims 1
- 230000008021 deposition Effects 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 230000027928 long-term synaptic potentiation Effects 0.000 claims 1
- 125000001419 myristoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 230000005062 synaptic transmission Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Claims (15)
1. GIP/GLP-1 ko-agonistički peptid predstavljen općom formulom I:
[image]
naznačen time što Xaa24 je Asn;
Y1 je Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-Lys (SEQ. ID. No. 7);
Y2 je odabran od:
Lys-Lys-Lys-Lys-Lys-Lys (SEQ. ID. No. 3); i
Arg-Arg-Gln-Arg-Arg-Lys-Lys-Arg-Gly-Tyr (SEQ. ID. No 4); i
R2 je -NH2,
ili farmaceutski prihvatljiva sol ili solvat peptida.
2. Peptid prema patentnom zahtjevu 1, naznačen time što se sastoji od aminokiselinske sekvence:
YXEGTFTSDYSIILDKQAAXEFVNWLLAGGPSSGAPPPSKKKKKK-NH2 (SEQ. ID. No. 11)
pri čemu X = aminoizomaslačna kiselina.
3. Peptid prema patentnom zahtjevu 1, naznačen time što se sastoji od aminokiselinske sekvence:
YXEGTFTSDYSIILDKQAAXEFVNWLLAGGPSSGAPPPSKRRQRRKKRGY-N H2 (SEQ. ID. No. 12)
pri čemu X = aminoizomaslačna kiselina.
4. Peptid prema bilo kojem prethodnom patentnom zahtjevu, naznačen time što sadrži hidrofilni dio koji je kovalentno vezan za aminokiselinu.
5. Peptid prema patentnom zahtjevu 4, naznačen time što sadrži hidrofilni dio koji je kovalentno vezan za (i) aminokiselinu na položaju 24 ili (ii) aminokiselinu na položaju 39 ili 40.
6. Peptid prema bilo kojem od patentnih zahtjeva 4 do 5, naznačen time što je hidrofilni dio vodotopivi polimer, pri čemu je izborno vodotopivi polimer dio polietilen glikola i izborno je dio polietilen glikola koji ima molekulsku masu između oko 20,000 Daltona i oko 60,000 Daltona.
7. Peptid prema bilo kojem prethodnom patentnom zahtjevu, naznačen time što je peptid konjugiran s lipofilnim supstituentom.
8. Peptid prema patentnom zahtjevu 7, naznačen time što lipofilni supstituent sadrži acilnu skupinu i izborno je molekula masne kiseline, te nadalje pri čemu je izborno molekula masne kiseline odabrana od C-8 oktanoilne skupine, C-10 dekanoilne skupine, C-12 lauroilne skupine, C-14 miristoilne skupine, C-16 palmitoilne skupine, C-18 stearoilne skupine i C-20 acilne skupine.
9. Peptid prema patentnom zahtjevu 7 ili zahtjevu 8, naznačen time što je lipofilni supstituent vezan za aminokiselinu na karboksilnom kraju peptida.
10. Peptid prema bilo kojem od patentnih zahtjeva 7 do 9, naznačen time što sadrži razmaknicu koja konjugira lipofilni supstituent na aminokiselinski ostatak.
11. Peptid prema patentnom zahtjevu 10, naznačen time što je razmaknica ostatak prirodne ili neprirodne aminokiseline, pri čemu razmaknica sadrži ostatak Gly, Pro, Ala, Val, Leu, Ile, Met, Cys, Phe, Tyr, Trp, His, Lys, Arg, Gln, Asn, α-Glu, γ-Glu, ε-Lys, Asp, Ser, Thr, Gaba, Aib, β-aminoheksonil, 7-aminoheptanoil, 8-aminooktanoil, 9-aminononanoil, 10-aminodekanoil ili 8-amino-3,6-dioksaoktanoil.
12. Peptid prema patentnom zahtjevu 11, naznačen time što je razmaknica γ-Glu ili pri čemu je razmaknica dipeptid, izborno gdje razmaknica sadrži dvije negativno nabijene aminokiseline i nadalje proizvoljno gdje je razmaknica γ-Glu- γ-Glu.
13. Peptid prema bilo kojem prethodnom patentnom zahtjevu, naznačen time što je za uporabu u liječenju i/ili profilaksi neurološkog poremećaja,
kao što je neurološki poremećaj koji je uzrokovan ili povezan s taloženjem plaka beta-amiloidnog proteina u području pacijenta,
ili neurološki poremećaj uzrokovan ili povezan s:
a) disfunkcijom dugotrajnog potenciranja sinaptičkog prijenosa; ili
b) upalom.
14. Peptid prema patentnom zahtjevu 13, naznačen time što je za uporabu u liječenju i/ili profilaksi neurološkog poremećaja koji utječe na kognitivnu funkciju, npr. demencija, moždani udar, shizofrenija i/ili bipolarni poremećaj, pri čemu je izborno poremećaj cerebralna ishemija povezana s moždanim udarom,
ili za uporabu u liječenju i/ili profilaksi poremećaja odabranog od posttraumatskog stresnog poremećaja, epilepsije, Touretteovog sindroma i halucinacija; i disfunkcionalnih kognitivnih procesa, koji su izborno odabrani od pažnje, računanja, pamćenja, prosuđivanja, uvida, učenja i obrazloženja,
ili za uporabu u liječenju i/ili profilaksi neurodegenerativnog poremećaja npr. Alzheimerove bolesti, Parkinsonove bolesti, amiotrofične lateralne skleroze, periferne neuropatije, Huntingtonove bolesti i Creutzfeldt-Jacobove bolesti,
ili za uporabu u liječenju i/ili profilaksi neurološkog poremećaja odabranog između kliničke ili predkliničke Alzheimerove bolesti, prodromalnog stadija Alzheimerove bolesti i kliničke ili pretkliničke amiloidne angiopatije (CAA).
15. Peptid za uporabu u liječenju i/ ili profilaksi kliničke Alzheimerove bolesti, te se peptid sastoji od slijedeće sekvence:
(a) YXEGTFTSDYSIILDKQAAXEFVNWLLAGGPSSGAPPPSKKKKKK-NH2 (SEQ ID No. 11)
pri čemu X = aminoizomaslačna kiselina; ili
(b) YXEGTFTSDYSIILDKQAAXEFVNWLLAGGPSSGAPPPSKRRQRRKKRGY-NH2 (SEQ ID No. 12)
pri čemu X = aminoizomaslačna kiselina.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1620611.2A GB201620611D0 (en) | 2016-12-05 | 2016-12-05 | Treatment of neurological diseases |
| EP17811693.5A EP3548061B1 (en) | 2016-12-05 | 2017-12-04 | Treatment of neurological diseases |
| PCT/GB2017/053655 WO2018104718A1 (en) | 2016-12-05 | 2017-12-04 | Treatment of neurological diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20201959T1 true HRP20201959T1 (hr) | 2021-04-16 |
Family
ID=58159786
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201959TT HRP20201959T1 (hr) | 2016-12-05 | 2020-12-07 | Liječenje neuroloških bolesti |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US11220534B2 (hr) |
| EP (1) | EP3548061B1 (hr) |
| JP (1) | JP7099729B2 (hr) |
| KR (1) | KR102600128B1 (hr) |
| CN (1) | CN110312520B (hr) |
| AU (1) | AU2017371811B2 (hr) |
| BR (1) | BR112019011462A2 (hr) |
| CA (1) | CA3044797A1 (hr) |
| CL (1) | CL2019001512A1 (hr) |
| CO (1) | CO2019006979A2 (hr) |
| CY (1) | CY1123623T1 (hr) |
| DK (1) | DK3548061T3 (hr) |
| ES (1) | ES2833408T3 (hr) |
| GB (1) | GB201620611D0 (hr) |
| HR (1) | HRP20201959T1 (hr) |
| HU (1) | HUE052766T2 (hr) |
| LT (1) | LT3548061T (hr) |
| MX (1) | MX2019006495A (hr) |
| PT (1) | PT3548061T (hr) |
| RS (1) | RS61230B1 (hr) |
| RU (1) | RU2755997C2 (hr) |
| SI (1) | SI3548061T1 (hr) |
| WO (1) | WO2018104718A1 (hr) |
| ZA (1) | ZA201903003B (hr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201620611D0 (en) * | 2016-12-05 | 2017-01-18 | Univ Of Lancaster | Treatment of neurological diseases |
| EP4185607A1 (en) | 2020-07-22 | 2023-05-31 | Novo Nordisk A/S | Co-agonists at glp-1 and gip receptors suitable for oral delivery |
| CN114617956B (zh) * | 2020-12-10 | 2023-10-03 | 江苏中新医药有限公司 | 一种高效降糖的蛋白质药物 |
| CN114042149B (zh) * | 2021-12-03 | 2023-06-16 | 中国人民解放军空军军医大学 | D-Ala2-GIP用于制备治疗焦虑症药物的应用 |
| TW202330584A (zh) | 2022-01-20 | 2023-08-01 | 丹麥商諾佛 儂迪克股份有限公司 | 前藥及其用途 |
| WO2023151594A1 (en) * | 2022-02-11 | 2023-08-17 | Hangzhou Sciwind Biosciences Co., Ltd. | A composition comprising gip receptor agonists and glp-1 receptor agonists and use thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2008132149A (ru) | 2006-01-05 | 2010-02-10 | Юниверсити Оф Юта Рисерч Фаундейшн (Us) | Способы и композиции, имеющие отношение к улучшенным свойствам фармакологических средств, целенаправленно действующих на нервную систему |
| PL2300035T3 (pl) * | 2008-06-17 | 2016-04-29 | Univ Indiana Res & Tech Corp | Mieszani agoniści na bazie GIP do leczenia zaburzeń metabolicznych i otyłości |
| JP2012505637A (ja) | 2008-10-15 | 2012-03-08 | アンジオケム，インコーポレーテッド | Ｇｌｐ−１アゴニストのコンジュゲート及びその使用 |
| RU2012136450A (ru) | 2010-01-27 | 2014-03-10 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Конъюгаты антагонист глюкагона - агонист gip и композиции для лечения метаболических расстройств и ожирения |
| EP2621945B1 (en) | 2010-09-28 | 2018-04-11 | NoNO Inc. | Nd2 peptides and methods of treating neurological disease |
| TWI559929B (en) * | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
| EP2766094B1 (en) | 2011-10-10 | 2019-03-06 | Lancaster University Business Enterprises Limited | Compositions for binding to amyloid proteins |
| IN2014MN02304A (hr) | 2012-05-03 | 2015-08-07 | Zealand Pharma As | |
| RU2015101697A (ru) * | 2012-06-21 | 2016-08-10 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Аналоги глюкагона, обладающие активностью рецептора gip |
| SG10202001285XA (en) | 2014-05-28 | 2020-04-29 | Nono Inc | Chloride salt of tat-nr2b9c |
| GB2528436A (en) | 2014-07-15 | 2016-01-27 | Lancaster Univ Business Entpr Ltd | Treatment of neurological diseases |
| US20160143920A1 (en) * | 2014-10-22 | 2016-05-26 | Morris Notelovitz | Composition, formulations and methods of making and using botanicals and natural compounds for the promotion of healthy brain aging |
| US20170112897A1 (en) | 2015-10-23 | 2017-04-27 | Cedars-Sinai Medical Center | Methods for treating brain insulin resistance |
| WO2017075522A2 (en) | 2015-10-28 | 2017-05-04 | Tufts University | Glp-2 polypeptides with improved proteolytic stability, and methods of preparing and using same |
| WO2017210168A1 (en) | 2016-06-02 | 2017-12-07 | Indiana University Research And Technology Corporation | Aqueously soluble and chemically stable depsi glucagon agonists |
| GB201620611D0 (en) * | 2016-12-05 | 2017-01-18 | Univ Of Lancaster | Treatment of neurological diseases |
-
2016
- 2016-12-05 GB GBGB1620611.2A patent/GB201620611D0/en not_active Ceased
-
2017
- 2017-12-04 JP JP2019529926A patent/JP7099729B2/ja active Active
- 2017-12-04 RU RU2019118165A patent/RU2755997C2/ru active
- 2017-12-04 HU HUE17811693A patent/HUE052766T2/hu unknown
- 2017-12-04 SI SI201730543T patent/SI3548061T1/sl unknown
- 2017-12-04 WO PCT/GB2017/053655 patent/WO2018104718A1/en active Application Filing
- 2017-12-04 AU AU2017371811A patent/AU2017371811B2/en active Active
- 2017-12-04 PT PT178116935T patent/PT3548061T/pt unknown
- 2017-12-04 US US16/466,194 patent/US11220534B2/en active Active
- 2017-12-04 BR BR112019011462A patent/BR112019011462A2/pt unknown
- 2017-12-04 ES ES17811693T patent/ES2833408T3/es active Active
- 2017-12-04 EP EP17811693.5A patent/EP3548061B1/en active Active
- 2017-12-04 CA CA3044797A patent/CA3044797A1/en active Pending
- 2017-12-04 CN CN201780075565.8A patent/CN110312520B/zh active Active
- 2017-12-04 LT LTEP17811693.5T patent/LT3548061T/lt unknown
- 2017-12-04 MX MX2019006495A patent/MX2019006495A/es unknown
- 2017-12-04 DK DK17811693.5T patent/DK3548061T3/da active
- 2017-12-04 KR KR1020197015601A patent/KR102600128B1/ko active IP Right Grant
- 2017-12-04 RS RS20201491A patent/RS61230B1/sr unknown
-
2019
- 2019-05-14 ZA ZA2019/03003A patent/ZA201903003B/en unknown
- 2019-06-04 CL CL2019001512A patent/CL2019001512A1/es unknown
- 2019-06-27 CO CONC2019/0006979A patent/CO2019006979A2/es unknown
-
2020
- 2020-12-07 HR HRP20201959TT patent/HRP20201959T1/hr unknown
- 2020-12-09 CY CY20201101167T patent/CY1123623T1/el unknown
-
2021
- 2021-10-13 US US17/500,430 patent/US11851468B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201959T1 (hr) | Liječenje neuroloških bolesti | |
| HRP20210809T1 (hr) | Biciklični peptidni ligandi specifični za mt1-mmp | |
| ES2602486T3 (es) | Análogos de glucagón que muestran actividad de receptor de GIP | |
| RU2496786C2 (ru) | Пептидные аналоги альфа-меланоцитстимулирующего гормона | |
| RU2012136450A (ru) | Конъюгаты антагонист глюкагона - агонист gip и композиции для лечения метаболических расстройств и ожирения | |
| ES2651113T3 (es) | Tratamientos terapéuticos dirigidos | |
| JP2012530145A5 (hr) | ||
| HRP20200503T1 (hr) | Fuzijski proteini | |
| JP2009532385A5 (hr) | ||
| HRP20171501T1 (hr) | Peptidi namijenjeni upotrebi u topikalnom liječenju neurodegenerativnih bolesti mrežnice, osobito u ranim stadijima dijabetične retinopatije i drugih bolesti mrežnice kod kojih neurodegeneracija ima ključnu ulogu | |
| JP2013518115A5 (hr) | ||
| JP2020007339A (ja) | α４β７インテグリンチオエーテルペプチドアンタゴニスト | |
| HRP20170535T1 (hr) | Tehnike za predviđanje, otkrivanje i smanjenje nespecifičnog ometanja proteina u testovima koji uključuju imunoglobulinske jednostruke varijabilne domene | |
| CR20140394A (es) | Anticuerpo monoclonal | |
| AR062065A1 (es) | Anticuerpo humanizado | |
| HRP20141215T1 (hr) | Analozi oksintomodulina | |
| HRP20140616T1 (hr) | Peptidni analog oksintomodulina | |
| JP2014524908A5 (hr) | ||
| WO2008113030A3 (en) | Treatment of leaky or damaged tight junctions and enhancing extracellular matrix | |
| JP2017529097A5 (hr) | ||
| JP2009532384A5 (hr) | ||
| JP2014504598A5 (hr) | ||
| WO2010111617A4 (en) | Parathyroid hormone peptides and parathyroid hormone-related protein peptides and methods of use | |
| JP2016510728A5 (hr) | ||
| WO2005115174A3 (fr) | Conjugues dipeptidiques antagonistes de l’alpha-msh |